Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We investigated whether therapeutic vaccination in highly active antiretroviral therapy (HAART)-treated patients with a modified vaccinia virus Ankara-vectored HIV-1 vaccine, with or without therapy interruption, induced the production of interleukin (IL)-10. Plasma IL-10 levels were not significantly increased postvaccination, but increased in parallel with viraemia in patients who interrupted therapy. Surprisingly, IL-10 blockade augmented HIV-specific T cell proliferative responses in HAART-suppressed patients but had no effect once virological control was lost. Modulation of IL-10 might enhance vaccine-induced immune responses.

Original publication

DOI

10.1097/QAD.0b013e328331a424

Type

Journal article

Journal

AIDS

Publication Date

23/10/2009

Volume

23

Pages

2226 - 2230

Keywords

AIDS Vaccines, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, HIV Infections, HIV-1, Humans, Interleukin-10, RNA, Viral, Viral Load